Source - PRN

Director Declaration

June 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Flemming Ornskov, MD, MPH, Chief Executive Officer of the Company, was appointed to the Board of Directors of Waters Corporation on June 22, 2017.

This notification is to satisfy the Company’s obligations under LR 9.6.14R of the UK Listing Rules.

Stephen Williams
Deputy Company Secretary

For further information please contact:

Investor Relations
Ian Karp [email protected] +1 781 482 9018
Robert Coates [email protected] +44 1256 894874
Media
Lisa Adler [email protected] +1 617 588 8607
Debbi Ford [email protected]  +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com